

Title (en)  
Compounds and methods of use

Title (de)  
VERBINDUNGEN UND ANWENDUNGSVERFAHREN

Title (fr)  
COMPOSÉS ET PROCÉDÉS D'UTILISATION

Publication  
**EP 2532657 A3 20130123 (EN)**

Application  
**EP 12182915 A 20091009**

Priority  
• EP 09821043 A 20091009  
• US 10541408 P 20081014

Abstract (en)  
[origin: US2010093727A1] The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

IPC 8 full level  
**C07D 401/12** (2006.01); **A61K 31/437** (2006.01); **A61P 35/00** (2006.01); **C07D 401/14** (2006.01); **C07D 405/12** (2006.01); **C07D 405/14** (2006.01); **C07D 413/14** (2006.01); **C07D 471/04** (2006.01); **C07D 491/107** (2006.01); **C07D 493/10** (2006.01); **C07D 495/04** (2006.01); **C07D 498/04** (2006.01); **C07D 519/00** (2006.01)

CPC (source: EP KR US)  
**A61K 31/437** (2013.01 - EP US); **A61K 31/444** (2013.01 - EP US); **A61K 31/4709** (2013.01 - EP KR US); **A61K 31/5377** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 401/12** (2013.01 - EP US); **C07D 401/14** (2013.01 - EP KR US); **C07D 405/12** (2013.01 - EP US); **C07D 405/14** (2013.01 - EP KR US); **C07D 413/14** (2013.01 - EP US); **C07D 471/04** (2013.01 - EP US); **C07D 491/107** (2013.01 - EP US); **C07D 493/10** (2013.01 - EP US); **C07D 495/04** (2013.01 - EP US); **C07D 498/04** (2013.01 - EP US); **C07D 519/00** (2013.01 - EP US)

Citation (search report)  
• [IY] WO 2006116713 A1 20061102 - AMGEN INC [US], et al  
• [Y] US 2004242603 A1 20041202 - FUJIWARA YASUNARI [JP], et al  
• [IY] US 2007244116 A1 20071018 - BANNEN LYNNE C [US], et al  
• [E] WO 2010111063 A1 20100930 - XI NING [US]  
• [Y] WO 2007059257 A2 20070524 - ARRAY BIOPHARMA INC [US], et al  
• [Y] WO 2007084875 A2 20070726 - CHEN GUOQING PAUL [US]  
• [IY] WO 2006108059 A1 20061012 - EXELIXIS INC [US], et al

Cited by  
CN105541798A; WO2021198709A1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)  
**US 2010093727 A1 20100415; US 8293897 B2 20121023**; AU 2009303602 A1 20100422; AU 2009303602 B2 20120614; BR PI0920261 A2 20150804; BR PI0920261 A8 20160119; CA 2740746 A1 20100422; EP 2340244 A1 20110706; EP 2340244 A4 20120725; EP 2532657 A2 20121212; EP 2532657 A3 20130123; EP 2532657 B1 20160831; EP 2532657 B9 20170419; ES 2599458 T3 20170201; HK 1172896 A1 20130503; JP 2012505888 A 20120308; JP 2015120733 A 20150702; JP 5734193 B2 20150617; JP 6058711 B2 20170111; KR 20110075016 A 20110705; MX 2011004018 A 20110624; RU 2011119478 A 20121127; US 2012315247 A1 20121213; US 8426585 B2 20130423; WO 2010045095 A1 20100422

DOCDB simple family (application)  
**US 57637509 A 20091009**; AU 2009303602 A 20091009; BR PI0920261 A 20091009; CA 2740746 A 20091009; EP 09821043 A 20091009; EP 12182915 A 20091009; ES 12182915 T 20091009; HK 12113565 A 20121231; JP 2011532153 A 20091009; JP 2015024856 A 20150212; KR 20117010711 A 20091009; MX 2011004018 A 20091009; RU 2011119478 A 20091009; US 2009060076 W 20091009; US 201213587936 A 20120817